NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Forecast, Price & News

$2.13

+0.04 (+1.91%)

(As of 09/27/2023 ET)

Compare

Today's Range: $2.05
▼
$2.23
50-Day Range: $2.03
▼
$2.89
52-Week Range: $1.90
▼
$7.15

Volume: 4,167 shs
Average Volume: 17,733 shs
Market Capitalization: $11.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Eterna Therapeutics (NASDAQ:ERNA) Stock

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

ERNA Price History

30 days | 90 days | 365 days | Advanced Chart

ERNA Stock News Headlines

September 13, 2023 | uk.finance.yahoo.com

Stem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: Visiongain

September 8, 2023 | finance.yahoo.com

Insider Stock Buying Reaches US$2.7m On Eterna Therapeutics

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 6, 2023 | finance.yahoo.com

Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies

September 6, 2023 | finance.yahoo.com

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

September 5, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

September 5, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors

July 18, 2023 | finance.yahoo.com

Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

July 11, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023 | finance.yahoo.com

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023 | finance.yahoo.com

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023 | marketwatch.com

Eterna Therapeutics Shares Rise 11% After Offer for Exacis Biotherapeutics Assets

May 2, 2023 | finance.yahoo.com

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

April 11, 2023 | marketwatch.com

Eterna Therapeutics Agrees to $10M Stock Purchase with Lincoln Park Capital

April 11, 2023 | finance.yahoo.com

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

March 28, 2023 | finance.yahoo.com

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

March 24, 2023 | seekingalpha.com

ERNA Eterna Therapeutics Inc.

March 20, 2023 | finance.yahoo.com

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

March 16, 2023 | finance.yahoo.com

Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m

February 3, 2023 | finance.yahoo.com

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

January 26, 2023 | msn.com

Eterna Therapeutics chief medical officer to resign

January 5, 2023 | marketwatch.com

Eterna Therapeutics Names Matt Angel as Permanent President, CEO >ERNA

January 4, 2023 | msn.com

Eterna appoints Matt Angel as CEO, President

January 4, 2023 | finance.yahoo.com

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

December 20, 2022 | finance.yahoo.com

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

See More Headlines

Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ERNA Company Calendar

Last Earnings: 8/11/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ERNA
CUSIP: N/A
CIK: 748592
Web: www.brooklynitx.com
Phone: (212) 582-1199
Fax: 760-438-3505
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -270.24%
Return on Assets: -82.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.54
Quick Ratio: 0.54

Sales & Book Value

Annual Sales: $5.80 million
Price / Sales: 1.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.12 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 5,410,000
Free Float: 3,493,000
Market Cap: $11.47 million
Optionable: Not Optionable
Beta: 4.27

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Matthew Angel Ph.D. (Age 42)
CEO & Pres
Comp: $240.8k

Ms. Sandra M. Gurrola (Age 56)
Principal Financial & Accounting Officer and VP of Fin.

Ms. Megan Yung
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ERNA Stock - Frequently Asked Questions

How have ERNA shares performed in 2023?: Eterna Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, ERNA stock has decreased by 34.2% and is now trading at $2.12.
View the best growth stocks for 2023 here.
Are investors shorting Eterna Therapeutics?: Eterna Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 130,500 shares, an increase of 21.3% from the August 31st total of 107,600 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 10.2 days. Currently, 4.4% of the company's shares are sold short.
View Eterna Therapeutics' Short Interest.
When is Eterna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ERNA earnings forecast.
How were Eterna Therapeutics' earnings last quarter?: Eterna Therapeutics Inc. (NASDAQ:ERNA) announced its earnings results on Friday, August, 11th. The company reported ($0.85) earnings per share for the quarter.

What is Eterna Therapeutics' stock symbol?: Eterna Therapeutics trades on the NASDAQ under the ticker symbol "ERNA."
Who are Eterna Therapeutics' major shareholders?: Eterna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sippican Capital Advisors (0.41%), BlackRock Inc. (0.34%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends.
How do I buy shares of Eterna Therapeutics?: Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eterna Therapeutics' stock price today?: One share of ERNA stock can currently be purchased for approximately $2.12.
How much money does Eterna Therapeutics make?: Eterna Therapeutics (NASDAQ:ERNA) has a market capitalization of $11.47 million and generates $5.80 million in revenue each year. The company earns $-24,580,000.00 in net income (profit) each year or ($5.64) on an earnings per share basis.
How can I contact Eterna Therapeutics?: Eterna Therapeutics' mailing address is 10355 Science Center Drive SUITE 150, San Diego CA, 92121. The official website for the company is www.brooklynitx.com. The company can be reached via phone at (212) 582-1199, via email at investors@brooklynitx.com, or via fax at 760-438-3505.

This page (NASDAQ:ERNA) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial